Abstract 16P
Background
In a phase of growing personalised medicine, predictive factors of treatment tolerance and response could be useful to tailor cancer patient’s care. Systemic inflammation, evaluated through inflammation scores, is known to correlate with prognosis and response to chemotherapy (ChT) in colorectal cancer (CRC), but there is scarce data about its association with ChT toxicity.
Methods
A retrospective study was performed, including patients diagnosed with CRC between January 2019 and December 2022 in a local Portuguese hospital, who underwent surgery and adjuvant ChT. Data regarding baseline systemic inflammation scores was collected, namely neutrophil-lymphocyte (NLR) and lymphocyte-monocyte (LMR) ratios and systemic imune-inflammation index (SII) given by platelets*neutrophils/lymphocytes. Adverse events (AEs) to ChT were collected according to version 5 of Common Terminology Criteria for Adverse Events. Descriptive analysis was performed using SPSS®. Correlation between inflammation scores and ChT toxicities was evaluated using Student’s T-test.
Results
117 patients were identified, with 61% males and a median age of 65. The most common ChT protocols were FOLFOX (50%), CAPOX (30%) and capecitabine (20%). Most (95%) patients experienced ChT-related AEs, including hematological (64%), neuropathy (60%), gastrointestinal (44%), and mucocutaneous (29%) AEs, with 17% experiencing grade 3/4 AEs. Median inflammation scores were NLR 3.0, LMR 3.4 and SII 858. All-grade neutropenia was found to significantly correlate to initial NLR (p=0,032), LMR (p=0,033) and SII (p=0,013); all-grade hematological toxicity correlated to SII (p=0,042); and ChT suspension due to any toxicity correlated with NLR (p=0,039). No significant correlation was found between inflammatory scores and non-hemtological AEs.
Conclusions
In this sample, initial inflammatory scores seemed to correlate and potentially predict hematological and suspension-leading toxicity. These correlations were not described in previous studies and they reinforce the influence of systemic inflammation in response to ChT, which can be of future use to tailor patient’s treatment in CRC.
Legal entity responsible for the study
Unidade Local de Saúde de Matosinhos.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.